The escalating demand for precision in cancer radiotherapy has driven innovation in nanomaterial-based radiosensitizers. This study investigates the mechanistic basis of radiation dose enhancement using polyacrylate-coated silver-titanium dioxide (PAA-TiO₂@Ag) core-shell nanoparticles, focusing on their interaction with ionizing radiation and biological systems. The synthesis strategy employed a controlled hydrothermal process followed by surface functionalization to yield stable, water-dispersible nanoparticles with optimal physicochemical properties. X-ray diffraction analysis confirmed crystalline phases of both TiO₂ (JCPDS 00-001-0562) and metallic Ag (JCPDS 01-1172), with peak shifts indicating successful interfacial bonding. Transmission electron microscopy revealed uniform core-shell morphologies, with an average particle size of 38.9 ± 2.17 nm, consistent with Scherrer calculations. Dynamic light scattering indicated a hydrodynamic diameter of 49.2 ± 3.13 nm after PAA coating, confirming effective polymer layer formation. Zeta potential measurements yielded −33 ± 1.4 mV, demonstrating strong colloidal stability through electrostatic repulsion.
A key focus was understanding the radiation interaction mechanisms underlying the observed dose enhancement. When exposed to ionizing radiation, these nanoparticles generate secondary electrons and reactive oxygen species (ROS) through radiolysis of surrounding water molecules. The high atomic number of silver (Z = 47) significantly enhances the photoelectric effect at low energies, leading to increased electron emission and energy deposition within tumor cells. This phenomenon is particularly pronounced under 80 kVp X-ray irradiation, where the energy dependence of the photoelectric cross-section scales as Z³/E³. In contrast, higher-energy gamma rays (1.25 MeV) exhibit reduced interaction probability due to dominance of Compton scattering, resulting in lower dose enhancement efficiency. Magnetic resonance imaging of MAGICA gel phantoms demonstrated this disparity clearly: at 8 Gy, DEF reached 1.44 for 80 kVp beams but only 1.20 for Co-60 gamma rays. The linear correlation between R₂ relaxation rate and absorbed dose further validated the reliability of the dosimetric response.
In vitro cytotoxicity assays using JA774A.1 macrophage cells showed that cell viability remained above 85% across all tested concentrations (0–200 mg/mL) after 24-hour exposure, with no significant difference from control groups (p > 0.05). Fluorescence microscopy confirmed intact cellular morphology, indicating minimal membrane disruption or apoptosis induction. These results highlight the exceptional biocompatibility conferred by the PAA shell, which prevents aggregation and reduces nonspecific protein adsorption. In vivo testing in Wistar rats confirmed safety over a seven-day intravenous administration period. No acute behavioral abnormalities were observed beyond transient hyperactivity post-injection. Body weight gain was comparable to controls, and histopathological evaluation of liver, kidney, spleen, heart, and gastrointestinal tissues revealed no signs of toxicity—no necrosis, inflammation, fibrosis, or vascular damage. Hematological parameters including WBC, HGB, MCV, platelets, and lymphocyte counts remained within normal ranges, reinforcing systemic tolerance.
The therapeutic implications are profound. By combining the intrinsic radiosensitizing capacity of silver with the photocatalytic activity of TiO₂ and the biocompatible stabilization of PAA, these nanoparticles offer a multifunctional platform.NIT2 Antibody Purity & Documentation They can selectively accumulate in tumor tissues via enhanced permeability and retention (EPR) effects, amplify radiation-induced DNA damage through localized ROS generation, and potentially enable theranostic applications through MRI contrast enhancement.GOLGA1 Antibody References Furthermore, their ability to function effectively under low-energy X-rays opens avenues for integration into conventional radiotherapy units without requiring specialized equipment.PMID:34261660
This research establishes PAA-TiO₂@Ag nanoparticles as a next-generation radiosensitizer with robust biocompatibility, predictable dose enhancement, and scalable synthesis. Future studies will explore their efficacy in orthotopic tumor models, assess synergistic effects with chemotherapeutic agents, and evaluate long-term biodistribution and clearance profiles. With continued refinement, these engineered nanomaterials may soon transition from bench to bedside, offering a safer, more effective approach to cancer radiotherapy.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
